certificate of analysis comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-12-12. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
By the early 2000s most lichen phylogenies analysed 3–5 genes (a few thousand base pairs in total). Frequently used loci were nuLSU rDNA, ITS (the standard barcode), and protein-coding fragments such as RPB1/2 or β-tubulin. Multilocus trees clarified family- and order-level relationships. They confirmed that almost all lichen-forming ascomycetes fall into three classes: Lecanoromycetes (the largest, e.g., Parmeliaceae, Lecanoraceae, Physciaceae), Eurotiomycetes (e.g., some Verrucaria), and Sordariomycetes (e.g., Graphidaceae). A small minority occur in the Basidiomycota (several agaric and clavarioid orders) or in smaller ascomycete classes. Thus molecular work placed lichens securely within the fungal tree, as Santesson had anticipated. The results prompted extensive revision; orders and families were reorganized to remove polyphyletic groups. For example, the pre-molecular 'Lecanorales' was divided into several orders (Lecanorales, Peltigerales, Teloschistales, etc.) after DNA data showed that superficially similar fruiting bodies did not imply close relationship. By the late 2000s a molecular phylogeny was routine in new taxonomic studies. Traditional methods remained important alongside molecular approaches. Morphology and chemistry remained essential: they guided sampling, framed hypotheses, and provided the diagnostic traits needed to circumscribe taxa. Many new species—particularly from biodiversity-rich regions—were still described from morphology alone or with a single DNA barcode.
Radionuclides are produced in stellar nucleosynthesis and supernova explosions along with stable nuclides. Most decay quickly, but some can be observed astronomically and can play a part in understanding astrophysical processes. Primordial radionuclides, such as uranium and thorium, still exist because their half-lives are so long (>100 million years) that the Earth's initial content has not yet completely decayed. Some radionuclides have half-lives so long (many times the age of the universe) that decay has only recently been detected, and for most practical purposes they can be considered stable, most notably bismuth-209: detection of this decay meant that bismuth was no longer considered stable. It is possible that decay may be observed in other nuclides now considered stable, adding to the list of primordial radionuclides. Secondary radionuclides are radiogenic isotopes derived from the decay of primordial radionuclides. They have shorter half-lives than primordial radionuclides. They arise in the decay chain of the primordial isotopes thorium-232, uranium-238, and uranium-235 - such as the natural isotopes of polonium and radium - some are also produced by natural fission and other nucleogenic processes. Cosmogenic isotopes, such as carbon-14, are present because they are continually being formed on Earth, typically in the atmosphere, due to the action of cosmic rays. Many of these radionuclides exist only in trace amounts in nature, including all cosmogenic nuclides.
=== Health === In a February 2026 livestream, part of an interview with The New York Times, Peters listed substances that were part of his daily routine, including testosterone, Accutane, retatrutide, and nebivolol. He began taking testosterone shots at 14. He also told The New York Times that he suspects he is sterile after years of injecting himself with testosterone and alluded to not necessarily enjoying the act of sex. Declaring himself infertile in the past due to testosterone injections, Peters explained: "So it's just like a negative feedback loop when you're not needing to produce testosterone anymore because your body realizes, okay, we're getting it from an outside source." Peters has stated that he is on the autism spectrum, although he has not been professionally diagnosed. He shared in a June 29, 2026, tweet that he used to stalk strangers so he could study neurotypical human behavior:
=== Sleep === Nicotine reduces the amount of rapid eye movement (REM) sleep, slow-wave sleep (SWS), and total sleep time in healthy nonsmokers given nicotine via a transdermal patch, and the reduction is dose-dependent. Acute nicotine intoxication has been found to significantly reduce total sleep time and increase REM latency, sleep onset latency, and non-rapid eye movement (NREM) stage 2 sleep time. Depressive non-smokers experience mood and sleep improvements under nicotine administration; however, subsequent nicotine withdrawal has a negative effect on both mood and sleep.
Sources: en.wikipedia.org
Afferent nerves conduct sensory information from sensory neurons to the central nervous system, for example from the mechanoreceptors in skin. Bundles of afferent fibers are known as sensory nerves. Efferent nerves conduct signals from the central nervous system along motor neurons to their target muscles and glands. Bundles of these fibres are known as efferent nerves. Mixed nerves contain both afferent and efferent axons, and thus conduct both incoming sensory information and outgoing muscle commands in the same bundle. All spinal nerves are mixed nerves, and some of the cranial nerves are also mixed nerves. Nerves can be categorized into two groups based on where they connect to the central nervous system:
=== Chemical precursor === Castor oil can react with other materials to produce other chemical compounds that have numerous applications. Transesterification followed by steam cracking gives undecylenic acid, a precursor to specialized polymer nylon 11, and heptanal, a component in fragrances. Breakdown of castor oil in strong base gives 2-octanol, both a fragrance component and a specialized solvent, and the dicarboxylic acid sebacic acid. Hydrogenation of castor oil saturates the alkenes, giving a waxy lubricant. Castor oil may be epoxidized by reacting the OH groups with epichlorohydrin to make the triglycidyl ether of castor oil which is useful in epoxy technology. This is available commercially as Heloxy 505. The production of lithium grease consumes a significant amount of castor oil. Hydrogenation of castor oil yields 12-hydroxystearic acid, a precursor to lithium 12-hydroxystearate, a thickener in lubricating greases. Since it has a relatively high dielectric constant (4.7), highly refined and dried castor oil is sometimes used as a dielectric fluid within high-performance, high-voltage capacitors.
For a definitive diagnosis to be made, symptoms must occur within 6 hours of transfusion, hypoxemia must be present, there must be radiographic evidence of bilateral infiltrates and there must be no evidence of left atrial hypertension (fluid overload). It occurs in 15% of the transfused patient with mortality rate of 5 to 10%. Recipient risk factors includes: end-stage liver disease, sepsis, haematological malignancies, sepsis, and ventilated patients. Antibodies to human neutrophil antigens (HNA) and human leukocyte antigens (HLA) have been associated with this type of transfusion reaction. Donor's antibodies interacting with antigen positive recipient tissue result in release of inflammatory cytokines, resulting in pulmonary capillary leakage. The treatment is supportive. Transfusion associated circulatory overload (TACO) is a common, yet underdiagnosed, reaction to blood product transfusion consisting of the new onset or exacerbation of three of the following within 6 hours of cessation of transfusion: acute respiratory distress, elevated brain natriuretic peptide (BNP), elevated central venous pressure (CVP), evidence of left heart failure, evidence of positive fluid balance, and/or radiographic evidence of pulmonary vascular congestion. Patients with congestive heart failure or kidney disease are more susceptible to volume overload. For especially vulnerable patients, a standard RBC unit could be split by sterile technique in the blood bank and administered over 8 hours instead of the standard 4 hours.
Sources: en.wikipedia.org
Cytochrome P-450 is not a single enzyme, but rather consists of a closely related family of 50 isoforms; six of them metabolize 90% of drugs. There is a tremendous diversity of individual P-450 gene products, and this heterogeneity allows the liver to perform oxidation on a vast array of chemicals (including most drugs) in phase 1. Three important characteristics of the P-450 system have roles in drug-induced toxicity:
In computer science, in situ refers to the use of technology and user interfaces to provide continuous access to situationally relevant information across different locations and contexts. Examples include athletes viewing biometric data on smartwatches to improve their performance or a presenter looking at tips on a smart glass to reduce their speaking rate during a speech. An algorithm is said to be an in situ algorithm, or in-place algorithm, if the extra amount of memory required to execute the algorithm is O(1). With big data, in situ data would mean bringing the computation to where data is located, rather than the other way like in traditional RDBMS systems where data is moved to computational space.
The division is heir to the Blue Division which fought during the Franco-Prussian War of 1870, in particular during the Battle of Bazeilles and the 9th Colonial Infantry Division, part of the Free French Forces, which distinguished themselves in the apprehending of Elba in June 1944 and the disembarking in Provence on 15 August of the same year. The Division then made way to Indochina, where it was placed dormant (without being dissolved) in December 1947. The unit was reactivated in July 1963 in Brittany under the designation of 9th Brigade. On 1 January 1976, the division was baptized as 9th Marine Infantry Division 9e DIMa. Accordingly, the division was attached to the terrestrial intervention force, then the Rapid Action Force (FAR) since 1983. On 1 July 1999, the unit was restructured in a brigade and was designated as 9th Light Armoured Marine Brigade (BLBMa). On 1 January 2013, the brigade was named to the current designation as the 9th Marine Infantry Brigade (9e BIMa). The headquarter staff is stationed in Poitiers since 1 July 2010. The motto of the brigade is "Semper et Ulbique", Latin for "Always and All over". The "9th" illustrated capability on all exterior theatres of operations where France has been engaged since World War II: Indochina, Lebanon, Kuwait, Macedonia, Kosovo, Bosnia, Congo, Tchad, Ivory Coast.
=== Ebola === After initial studies by the Centers for Disease Control and Prevention (CDC, Atlanta, Georgia, US) in cell culture models, on 6 October 2014, Chimerix received an FDA authorization for emergency investigational new drug applications of brincidofovir for the treatment of Ebola virus disease. Brincidofovir was administered to the first patient diagnosed in the Ebola virus disease outbreak in the US in 2014. The patient was given the drug starting six days after hospital admission when he was already critically ill; he died four days later. Brincidofovir was also given to Ebola patient Ashoka Mukpo at the Nebraska Medical Center, who had developed the disease and then was pronounced Ebola-free and released from the center on 22 October 2014. In October 2014, Chimerix reported it had been given approval by the FDA to start Phase 2 trials in patients infected with ebolaviruses for brincidofovir's safety, tolerability, and efficacy. Organised by a team of scientists at the University of Oxford, including Peter Horby, Jake Dunning, Laura Merson and Trudie Lang, a trial commenced during January 2015 in Liberia, but was subsequently discontinued. Because of a lack of suitable subjects in Liberia, Oxford University and Médecins Sans Frontières planned to extend the trial to Sierra Leone, where there were still Ebola cases; but on 30 January 2015, the manufacturer decided to withdraw support for the trial and end discussion of future trials.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.